© 2022 MJH Life Sciences and Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways. All rights reserved.
© 2022 MJH Life Sciences™ , Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways. All rights reserved.
December 05, 2022
Wenxin (Vincent) Xu, MD, provides insight on biomarkers in renal cell carcinoma.
November 30, 2022
Following positive new data from a phase 1/2 study examining batiraxcept in patients with clear cell renal cell carcinoma, the agent has been granted fast track designation by the FDA.
November 25, 2022
During a Targeted Oncology case-based roundtable event, Eric Jonasch, MD, discussed the efficacy of the CheckMate 9ER regimen for patients with renal cell carcinoma.
November 19, 2022
In an interview with Targeted Oncology, Karie Runcie, MD, provided an assessment on the Clavien-Dindo classification system and discussed initial results of the Cyo-KIK trial.
November 11, 2022
Bradley A. McGregor, MD, discusses current and future second-line therapy options following frontline tyrosine kinase inhibitor and immunotherapy for patients with advanced renal cell carcinoma.
Toni K. Choueiri, MD, discusses a key next step for using pembrolizumab in the treatment of renal cell carcinoma.
November 10, 2022
Retrospective analysis of a phase 2 trial indicated that tivozanib demonstrated efficacy and tolerability in the subset of patients who had non-clear cell histologies of renal cell carcinoma.
November 09, 2022
Scott Tykodi, MD, PhD, discusses using DFS as a primary end point in trials, as well as the usage of biomarkers.
Moshe Ornstein, MD, MA, discusses his approach to adjuvant therapy while treating patients with advanced clear cell RCC.
Nizar Tannir, MD, describes the data, criteria, and end points of the KEYNOTE-564 trial.